Rapid Dose Therapeutics

The Team at RDT was honoured to host Associate Minister of Small Business and Red Tape Reduction Prabmeet Singh Sarkaria, MPP Effie Triantafilopoulos and MPP Stephen Crawford for tour of our facility and a productive meeting to discuss our technology and the benefits of a rapid sublingual drug delivery system designed to improve healthcare outcomes and quality of lives.

PRESS RELEASE: September 29, 2020 Rapid Dose Therapeutics is pleased to announce it has amended the agreement with Aphria Inc. (TSE: APH Nasdaq: APHA) signed Nov 1, 2018. The amended agreement enables RDT to produce the QuickStrip at its licensed Burlington facility for Aphria. As part of the amendment, Aphria relinquishes its global exclusive preferred vendor status enabling RDT to enter new markets with other licensed producers. Mark Upsdell, RDT CEO, adds "This change i...s consistent with the way we prefer to access developing markets. Non-exclusivity enables RDT to reach more Canadian medical and recreational users than available through a single customer strategy and opens up global opportunities. We also look forward to establishing agreements in emerging markets to provide the innovative QuickStrip." Jason Lewis, RDT SVP Business Development said, "This is an exciting step forward providing us the capability of producing QuickStrip for Canadian licensed producers seeking product delivery diversification. Adults who use medical and recreational cannabis will benefit from our proprietary delivery technology that offers a Quick, Convenient, Precise, and Discreet way to consume CBD and THC." Upsdell adds, "RDT and Aphria have a long term relationship that is continuing to evolve as business plans, processes and markets change in Canada and internationally. Moving Aphria strip production into RDT's own facility enables RDT to focus on its core competencies." With regard to the CTO, the Company is working diligently with its auditors on the completion of the Annual Filings. In addition to its annual filings, the company is also working toward the completion and filings of its MDNA and first quarter filings. For more information and to view the full release visit RDT at www.rapid-dose.com

PRESS RELEASE: Burlington, Ontario August 13, 2020 Rapid Dose Therapeutics Corp announces the appointment of Mr. Peter Thilo Hasler to the board of directors. Mark Upsdell, CEO of RDT said We are excited to welcome Peter to our board of directors and assuming an important role as a independent member of the audit committee. He brings decades of leadership in key financial areas, an in-depth understanding of the European investment community, and a broad network of German... institutional equity and bond investors, family offices, and asset managers. RDT’s announcement yesterday of its credit facility financing provides RDT with the resources to exploit opportunities in the European market for its nutraceutical products, cannabis, and pharmaceutical lines. Hasler’s appointment to the board provides RDT with European market access to financial and business relationships to facilitate and support RDT’s entry into the European market. Read Full Press Release Here: https://bit.ly/3iFMH4r

PRESS RELEASE: RDT announces that the Company, in conjunction with Leede Jones Gable, has received an initial advance from a strategic industry investor of $500,000 of financing as part of a proposed $6,000,000 credit facility. The financing comes from a lender with upstream assets who recognized the significance of the RDT technology and business model to allow for the rapid deployment of QuickStrip into the global markets. The high margin opportunity in the THC and CBD markets was key to the decision to select RDT as an investment opportunity. Read Full Release here: https://bit.ly/3gVIvgI

Press Release: Rapid Dose Therapeutics Files a Patent to Synthesize THC From CBD Using a Selective Delta 8 or Delta 9 Conversion Process - June 19, 2020 RDT is pleased to announce it has filed a non-provisional patent with the USPTO for an Apparatus for and method of converting cbd and/or cbd derivatives to at least one other type of cannabinoid and/or cannabinoid derivative such as THC. In conjunction with McMaster University and the team lead by Dr. James McNulty, RDT has... discovered a new and efficient way to create THC from CBD. This selective method can generate delta 8 or delta 9 THC. Jason Lewis, RDT SVP and co-inventor said this is an incredible breakthrough for RDT and the industry as a whole. Our technology could revolutionize the way synthetic THC is created so patients around the world can have access to a consistent quality of delta 8 or delta 9. Instead of the industry being dependent on the many complicated variables associated with growing cannabis and the expense of cultivating indoors, we created a method to convert hemp-derived CBD to THC. This is the innovation required to allow pharmaceutical companies to embrace cannabinoid treatments. Read the full release here: https://bit.ly/2ZOXl2b #QuickStrip #RapidDose #cannabis $DOSE

Press Release: RDT Signs agreement with Leede Jones Gable to provide Financial Advisory Services and Announces Change to its Board of Directors Read the full release here: https://bit.ly/3eSoTrY #QuickStrip #RapidDose $DOSE

RDT is pleased to announce an Agreement with Perennial Brands, a DCM company, for the distribution and sale of nutraceutical oral dissolvable strip products in Canada, the United States and India for a period of three years. RDT is excited to continue to offer QuickStrip nutraceutical product formulations that are Quick, Convenient, Precise, and Discreet to Canadian, US and Indian audiences, said Mark Upsdell, CEO, Rapid Dose Therapeutics. This Agreement will continue ...to strengthen and accelerate our objective to deliver a consistent, premium, consumer-focused health and wellness product to global markets. Read the full release here http://bit.ly/3a74BJh #QuickStrip #nutraceuticals #lifescience #rapiddose $DOSE

PRESS RELEASE: Burlington, Ontario, August 11, 2020. Rapid Dose Therapeutics Corp. is pleased to announce it has begun COVID-19 vaccine research in conjunction with McMaster University and the team lead by Drs. Alex Adronov, James Mahony, and Mark Larché. The federally-funded project tests the use of QuickStrip for administering vaccines orally as a convenient and safe alternative to injection with needles, the currently accepted delivery format for most vaccines. Dr. Adro...nov is a recognized Canadian expert in synthetic polymer chemistry and the development of novel polymer architectures, Dr. Mahony has extensive experience in virology and vaccine development, and Dr. Larché is an immunologist with expertise in vaccine research geared toward treatment of common allergies. The combined expertise of this research team will enable development and evaluation of oral vaccine delivery strategies. Jason Lewis, RDT SVP said RDT is focused on novel research through collaboration with the experts at McMaster. We see QuickStrip, oral mucosa thin film delivery, as an efficient solution for distributing vaccines globally. Experts believe that antigens to COVID and other viruses can be delivered sublingually, a much easier and less expensive process than the current single or multidose vial methods. Imagine the significance of creating a vaccine that can be sent in an envelope, by mail. Read the full release here: https://bit.ly/39iB9Ri #quickstrip #rapiddose #COVID19 #mcmasteruniversity $DOSE